EP0689610A1 - Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease - Google Patents

Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease

Info

Publication number
EP0689610A1
EP0689610A1 EP94911643A EP94911643A EP0689610A1 EP 0689610 A1 EP0689610 A1 EP 0689610A1 EP 94911643 A EP94911643 A EP 94911643A EP 94911643 A EP94911643 A EP 94911643A EP 0689610 A1 EP0689610 A1 EP 0689610A1
Authority
EP
European Patent Office
Prior art keywords
mass
exonuclease
modified
nucleic acid
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP94911643A
Other languages
English (en)
French (fr)
Other versions
EP0689610B1 (de
Inventor
Hubert KÖSTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequenom Inc
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Publication of EP0689610A1 publication Critical patent/EP0689610A1/de
Application granted granted Critical
Publication of EP0689610B1 publication Critical patent/EP0689610B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6872—Methods for sequencing involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1065—Multiple transfer devices
    • G01N35/1067—Multiple transfer devices for transfer to or from containers having different spacing

Definitions

  • the current state-of-the-art in DNA sequencing is summarized in recent review articles [e.g. B. Barrell, The FASEB Journal. £, 40 (1991); G.L. Trainor, Anal. Chem. 62, 418 (1990), and references cited therein].
  • the most widely used DNA sequencing chemistry is the enzymatic chain termination method [F. Sanger et al., Proc. Natl. Acad. Sci. USA. 74. 5463 (1977)] which has been adopted for several different sequencing strategies.
  • the sequencing reactions are either performed in solution with the use of different DNA polymerases, such as the thermophilic Taq DNA polymerase [M. A. Innes, Proc. Natl. Acad. Sci. USA.
  • PAGE as an integral part, however, is the generation of reliable sequence information, and the transformation insert of this information into a computer format to facilitate sophisticated analysis of the sequence data utilizing existing software and DNA sequence and protein data banks.
  • standard Sanger sequencing 200 to 500 bases of unconfirmed sequence information could be obtained in about 24 hours; with automatic DNA sequencers this number could be multiplied by approximately a factor of 10 to 20 due to processing several samples simultaneously.
  • a further increase in throughput could be achieved by employing multiplex DNA sequencing [G. Church et al., Science. 240. 185-188 (1988); K ⁇ ster et al., Nucleic Acids Res. Symposium Ser. No. 24.
  • a large scale sequencing project often starts with either a cDNA or genomic library of large DNA fragments inserted in suitable cloning vectors such as cosmid, plasmid (e.g. pUC), phagemid (e.g. pEMBL, pGEM) or single-stranded phage (e.g. Ml 3) vectors
  • suitable cloning vectors such as cosmid, plasmid (e.g. pUC), phagemid (e.g. pEMBL, pGEM) or single-stranded phage (e.g. Ml 3) vectors
  • PAGE In PAGE, under denaturing conditions the nested families of terminated DNA fragments are separated by the different mobilities of DNA chains of different length. A closer inspection, however, reveals that it is not the chain length alone which governs the mobility DNA chains by PAGE, but there is a significant influence of base composition on the mobility [R. Frank and H. Koster, Nucleic Acids Res.. £, 2069 (1979)]. PAGE therefore is not only a very slow, but also an unreliable method for the determination of molecular weights, as DNA fragments of the same length but different sequence/base composition could have different mobilities. Likewise, DNA sequences which have the same mobility could have different sequence/base compositions.
  • Mass spectrometry is capable of doing this.
  • the enormous advantage of mass spectrometry compared to the above mentioned methods is the speed, which is in the range of seconds per analysis, and the accuracy of mass determination, as well as the possibility to directly read the collected mass data into a computer.
  • the application of mass spectrometry for DNA sequencing has been investigated by several groups [e.g. Methods in Enzymology. Vol. 193: Mass Spectrometry, (J.A. McCloskey, editor), 1990. Academic Press, New York; K.H. Schramm Biomedical Applications of Mass Spectrometrv.24, 203-287 (1990); P.F. Crain Mass Spectrometry Reviews, 505 (1990)].
  • MALDI and ES mass spectrometry are in some aspects complementary techniques. While ES, using an atmospheric pressure ionization interface (API), can accommodate continuous flow streams from high-performance liquid chromatoghraphs
  • ES mass spectrometry While the high mass range in ES mass spectrometry is accessible through the formation of multiply charged molecular ions, this is achieved in MALDI mass spectrometry by applying a time-of- flight (TOF) mass analyzer and the assistance of an appropriate matrix to volatilize the biomolecules. Similar to ES, a thermospray interface has been used to couple HPLC on-line with a mass analyzer. Nucleosides originating from enzymatic hydrolysates have been analyzed using such a configuration [CG. Edmonds et al. Nucleic Acids Res..12, 8197-8206 (1985)]. However, Edmonds et al. does not disclose a method for nucleic acid sequencing.
  • a complementary and completely different approach to determine the DNA sequence of a long DNA fragment would be to progressively degrade the DNA strand using exonucleases from one side - nucleotide by nucleotide.
  • This method has been proposed by Jett et al. See J.H. Jett et al. J. Biomolecular Structure & Dynamics.2, 301-309 (1989); and J.H. Jett et al. PCT Application No. WO 89/03432.
  • a single molecule of a DNA or RNA fragment is suspended in a moving flow stream and contacted with an exonuclease which cleaves off one nucleotide after the other. Detection of the released nucleotides is accomplished by specifically labeling the four nucleotides with four different fluorescent dyes and involving laser induced flow cytometric techniques.
  • the invention described here addresses most of the problems described above inherent to currently existing DNA sequencing processes and provides chemistries and systems suitable for high-speed DNA sequencing a prerequisite to tackle the human genome (and other genome) sequencing projects.
  • the process of this invention does not use the Sanger sequencing chemistry, polyacrylamide gel electrophoresis or radioactive, fluorescent or chemiluminescent detection. Instead the process of the invention adopts a direct sequencing approach, beginning with large DNA fragments cloned into conventional cloning vectors, and based on mass spectrometric detection. To achieve this, the DNA is by means of protection, specificity of enzymatic activity, or immobilization, unilaterally degraded in a stepwise manner via exonuclease digestion and the nucleotides or derivatives detected by mass spectrometry.
  • phasing problem can be resolved by continuously applying small quantities of the enzymatic reaction mixture onto a moving belt with adjustable speed for mass spectrometric detection.
  • the throughput could be further increased by applying reaction mixtures from different reactors simultaneously onto the moving belt.
  • the different sets of sequencing reactions can be identified by specific mass-modifying labels attached to the four nucleotides.
  • Two- dimensional multiplexing can further increase the throughput of exonuclease mediated mass spectrometric sequencing as being described in this invention.
  • FIGURE 1 illustrates a process of exonuclease sequencing beginning with a single-stranded nucleic acid.
  • FIGURE 2 illustrates a process similar to FIGURE 1, however, starting with a target nucleic acid inserted into a double-stranded vector.
  • FIGURE 3 illustrates a method for introducing mass-modified nucleotides into a target nucleic acid sequence multiplexing mass spectrometry.
  • FIGURE 4A and 4B illustrate methods for introducing mass-modified nucleotides into a target nucleic acid sequence multiplexing mass spectrometry.
  • FIGURE 5 shows positions within a nucleic acid molecule which can be modified for the introduction of discriminating mass increments or modulation of exonuclease activity.
  • FIGURE 6 illustrates various structures of modified nucleoside triphosphates useful for the enzymatic incorporation of mass-modified nucleotides into the DNA or RNA to be sequenced.
  • FIGURE 7 shows some possible functional groups (R) useful to either mass- modification of nucleotides in discrete increments for differentiation by mass spectrometry and/or to modulate the enzymatic activity of an exonuclease.
  • FIGURE 8 illustrates some linking groups X for the attachment of the mass modifying functionality R to nucleosides.
  • FIGURE 9 is a schematic drawing of a sequencing reactor system.
  • FIGURE 10 is a graphical representation of idealized output signals following the time-course of the stepwise mass spectrometric detection of the exonucleolytically released nucleotides.
  • FIGURE 1 1 illustrates specific labels introduced by mass modification to facilitate multiplex exonuclease mass spectrometric sequencing.
  • FIGURE 12 is a schematic drawing of a moving belt apparatus for delivering single or multiple tracks of exonuclease samples for laser induced mass spectrometric sequence determination in conjunction with the sequencing reactor of FIGURE 9.
  • FIGURE 13 is a schematic representation of individually labeled signal tracks employed in multiplex exonuclease mediated mass spectrometric sequencing.
  • FIGURES 14A and 14B illustrate a method for double-stranded exonuclease sequencing for mass spectrometric sequence determination. Detailed Description Of The Invention
  • the starting point for the process of the invention can be, for example, DNA cloned from either a genomic or cDNA library, or a piece of DNA isolated and amplified by polymerase chain reaction (PCR) which contains a DNA fragment of unknown sequence.
  • Libraries can be obtained, for instance, by following standard procedures and cloning vectors [Maniatis, Fritsch and Sambrook (1982), supra; Methods in Enzymology, Vol. 101 (1983) and Vol. 152-155 (1987). supra]. Appropriate cloning vectors are also commercially available.
  • the invention is not limited to the use of any specific vector constructs and cloning procedures, but can be applied to any given DNA fragment whether obtained, for instance, by cloning in any vector or by the Polymerase Chain Reaction (PCR).
  • PCR Polymerase Chain Reaction
  • the unknown DNA sequence can be obtained in either double-stranded form using standard PCR or in a single-stranded form employing asymmetric PCR [PCR Technology: Principles and Applications for DNA Amplification (Erlich, editor), M. Stockton Press, New York
  • DNA and RNA can be exonucleolytically degraded from either the 5 1 or 3' end depending upon the choice of exonuclease.
  • sequence of an unknown DNA molecule can be determined directly by exonuclease digestion, or alternatively, the DNA fragment of unknown sequence can be transcribed first into a complementary RNA copy which is subsequently exonucleolytically degraded to provide the RNA sequence.
  • Appropriate vectors such as the pGEM (Promega) vectors, are useful in the present as they have specific promoters for either the SP6 or T7 DNA dependent RNA polymerases flanking the multiple cloning site.
  • these vectors belonging to the class of phagemid vectors, provide means to generate single stranded DNA of the unknown double stranded DNA.
  • both strands of the unknown DNA sequence can be obtained in a single stranded form and utilized for subsequent exonuclease sequencing.
  • the scope of the invention is also not limited by the choice of restriction sites. There is, however, a preference for rare cutting restriction sites to keep the unknown DNA fragment unfragmented during the manipulations in preparation for exonuclase sequencing.
  • FIGURE 1 describes the process for a single stranded DNA insert ("Target DNA") of a single stranded circular cloning vector.
  • the boundaries of the target DNA are designated A and B.
  • the target DNA as illustrated in FIGURE 1, has been cloned into the Not I site of a vector.
  • a synthetic oligodeoxynucleotide [N.D. Sinha, J. Biernat, J. McManus and H. Koster, Nucleic Acids Res..12, 4539 (1984)] which will restore the Not I site to double-strandedness and which is complementary to the vector sequence flanking the A boundary of the insert DNA is hybridized to that site and cleaved by Not I restriction endonuclease.
  • the two pieces of the synthetic oligodeoxynucleotide can then be removed by molecular sieving, membrane filtration, precipitation, or other standard procedures.
  • FIGURE 1 also illustrates a set of ordered deletions (t°, t 1 , t- 2 , t 3 ) which can be obtained by the time-limited action of an exonuclease, e.g. T4 DNA polymerase, in the absence of dNTPs.
  • the set of deletions can be immobilized on a solid support Tr (Tr ⁇ , Tr 1 , Tr2, Tr 3 ), or alternatively, the set of ordered deletions can be obtained in a heterogeneous reaction by treating the solid support TrO containing the complete target DNA sequence with an exonuclease in a time-limited manner.
  • a single stranded linear DNA fragment carrying the unknown sequence with its A boundary at the 3' end can be directly sequenced by an 3' exonuclease in an apparatus described below and schematically depicted in FIGURE 9, provided that the exonuclease is immobilized within the reactor on, for example, beads, on a frit, on a membrane located on top of the frit or on the glass walls of a capillary or entrapped in a gel matrix or simply by a semipermeable membrane which keeps the exonuclease in the reactor while the linear DNA fragment is circulating through a loop.
  • the reaction mixture containing the buffer and the released nucleotides is fed to the mass spectrometer for mass determination and nucleotide identification.
  • the stream containing the nucleotides released by exonuclease action can be passed through a second reactor or series of reactors which cause the released nucleotide to be modified.
  • the second reactor can contain an immobilized alkaline phosphatase and the nucleotides passing therethrough are transformed to nucleosides prior to feeding into the mass spectrometer. Other mass-modifications are described below.
  • the modification should take as few steps as possible and be relatively efficient.
  • reactions used in adding base protecting groups for oligonucleotide synthesis can also be used to modify the released nucleotide just prior to mass spectrometric analysis.
  • the amino function of adenine, guanine or cytosine can be modified by acylation.
  • the amino acyl function can be, by way of illustration, an acetyl, benzoyl, isobutyryl or anisoyl group.
  • Benzoylchloride in the presence of pyridine, can acylate the adenine amino group, as well as the deoxyribose (or ribose) hydroxyl groups.
  • the sugar moiety can be selectively deacylated if the acyl reaction was not efficient at those sites (i.e., heterogeneity in molecular weight arising from incomplete acylation of the sugar).
  • the sugar moiety itself can be the target of the mass-modifying chemistry.
  • the sugar moieties can be acylated, tritylated, monomethoxytritylated, etc.
  • Other chemistries for mass-modifying the released nucleotides (or ribonucleotides) will be apparent to those skilled in the art.
  • the linear single stranded DNA fragment can be anchored to a solid support.
  • This can be achieved, for example, by covalent attachment to a functional group on the solid support, such as through a specific oligonucleotide sequence which involves a spacer of sufficient length for the ligase to react and which is covalently attached via its 5' end to the support (FIGURE 1).
  • a splint oligonucleotide with a sequence complementary in part to the solid bound oligonucleotide and to the 5' end of the linearized single stranded vector DNA allows covalent attachment of the DNA to be sequenced to the solid support.
  • ligation covalently links the solid bound oligonucleotide and the DNA to be sequenced.
  • the splint oligonucleotide can be subsequently removed by a temperature jump and/or NaOH treatment, or washed off the support using other standard procedures.
  • the solid support with the linear DNA example is transferred to the reactor (FIGURE 9) and contacted with an exonuclease in solution. As illustrated, where the 3 1 end of the unknown DNA fragment is exposed (ie unprotected), a 3' exonuclease is employed.
  • the solid supports can be of a variety of materials and shapes, such as beads of silica gel, controlled pore glass, cellulose, polyacrylamide, sepharose, sephadex, agarose, polystyrene and other polymers, or membranes of polyethylene, polyvinylidendifluoride (PVDF) and the like.
  • the solid supports can also be capillaries, as well as frits from glass or polymers.
  • Various 3' exonucleases can be used, such as phosphodiesterase from snake venom, Exonuclese VII from E. coli, Bal 31 exonuclease and the 3'-5' exonuclease activity of some DNA polymerases exerted in the absence of dNTPs, as for example T4 DNA polymerase.
  • the B boundary In using a phagemid vector with an inverted fl origin of replication, the B boundary would be located at the 3' end of the immobilized linear single stranded DNA and exposed to exonuclease sequencing using the same restriction endonuclease, hybridizing oligodeoxynucleotide and splint oligonucleotide.
  • the hybridizing oligonucleotide can also be designed to bind a promoter site upstream of the A boundary and by doing so restoring the doublestranded promoter DNA.
  • transcription can be initiated with the appropriate specific DNA dependent RNA polymerase [Methods in Enzymology. Vol. 185, Gene Expression Technology (1990): J.F. Milligan, D.R. Groebe, G.W. Witherell and O.C Uhlenbeck. Nucleic Acids Res., li, 8783-98 (1987); C. Pitulle, R.G. Kleineidam, B. Sproat and G. Krupp, Gene. Ul, 101-105 (1992) and H. Koster US Patent Application No. 08/001,323, supra].
  • the RNA transcript can be transferred to the reactor (FIGURE 9) and contacted with an immobilized or otherwise contained exonuclease, or immobilized via the 5' functionality of the initiator oligonucleotide incorporated in the RNA transcript to a solid support and then contacted with an exonuclease in solution.
  • the mass spectrometric exonuclease sequencing process can allow the complete sequence from A to B to be determined in one run.
  • a set of ordered deletions can be prepared according to standard procedures [e.g. Methods in Enzymology. Vol. 101 (1983) and Vol. 152-155 (1987): R.M.K. Dale et al., Elasmi , 12, 31-40 (1985)], such that, in FIGURE 1 the steps TrO to Tr 3 can represent either different time values of the mass spectrometric exonuclease sequencing reaction from immobilized DNA fragments or different starting points for the exonuclease DNA RNA mass spectrometric sequencing process. In either case the principle of the invention described provides a process by which the total sequence of the insert can be determined.
  • the unknown DNA sequence (target DNA) is inserted into a double-stranded cloning vector (FIGURE 2) or obtained in double- stranded form, as for example by a PCR (polymerase chain reaction) process [PCR Technology. (1989) supra].
  • the DNA to be sequenced is inserted into a cloning vector, such as ligated into the Note I site as illustrated in Figure 2. Adjacent to the A boundary there can be located another cutting restriction endonuclease site, such as an Asc I endonuclease cleavage site.
  • the double-stranded circular molecule can be linearized by treatment with Asc I endonuclease and ligated to a solid support using a splint oligodeoxynucleotide (and ligase) as described above which restores the Asc I restriction site (Tr ⁇ ds and Tr ⁇ 'ds).
  • the strand which is not immobilized can be removed by subjecting the double stranded DNA to standard denaturing conditions and washing, thereby generating single-stranded DNAs immobilized to the solid support (Tr ⁇ ss and Tr ⁇ 'ss).
  • the immobilized fragment which carries the vector DNA sequence at the 3' end can be protected from 3' exonuclease degradation during the sequencing process by, for example, annealing with an oligodeoxynucleotide complementary to the 3' end of the strand to be protected.
  • alpha-thio dNTP's can be incorporated into the immobilized (-) strand via treatment with a DNA polymerase and completely protect that strand from exonucleolytic degradation [P.M.J. Burgers and F. Eckstein, Biochemistry. __[, 592 (1979); S. Labeit, H. Lehrach and R.S. Goody, DNA. £, 173 (1986); S. Labeit, H. Lehrach and R.S. Goody in Methods in Enzymology. Vol. 155, page 166 (1987). supra].
  • the oligonucleotide primer may be removed by a washing step under standard denaturing conditions.
  • the immobilized single- stranded DNAs are transferred to the sequencing reactor (FIGURE 9) and the sample with the unknown sequence at the 3' end is degraded by an exonuclease in a stepwise manner.
  • the liberated nucleotides, or optionally modified nucleotides, are continuously fed into the mass spectrometer to elucidate the sequence.
  • deletion mutants can be recircularized and used to transform host cells following standard procedures.
  • Single colonies of the transformed host cells are selected, further proliferated, and the deletion mutant isolated and immobilized as single-stranded DNAs, similar to the process described above and subsequently analyzed by exonuclease mass spectrometric sequencing.
  • the immobilized full length single stranded DNA can be treated in time-limited reactions with an exonuclease such as T4 DNA polymerase in the absence of NTPs, to create a set of immobilized ordered deletions for subsequent exonuclease mass spectrometric sequencing.
  • an intermediate cloning step can be included.
  • the exonuclease mediated sequencing can be performed by providing the single-stranded (ss) nucleic acid fragment in solution. This can be achieved by treating the solid support, e.g. Tr ⁇ ss, with an oligonucleotide complementary to the unique Asc I site. After hybridization this site is now double-stranded (ds) and susceptible to Asc I endonuclease cleavage and release of the single-stranded fragment.
  • ss single-stranded nucleic acid fragment in solution.
  • Tr ⁇ ss oligonucleotide complementary to the unique Asc I site. After hybridization this site is now double-stranded (ds) and susceptible to Asc I endonuclease cleavage and release of the single-stranded fragment.
  • both strands of the double-stranded target DNA can be transcribed separately dependant upon which of the specific promoters flanking the insertion site is used (located next to the A or B boundary of the insert, FIGURE 2) and the corresponding specific DNA dependent RNA polymerase (i.e., SP6 or T7 RNA polymerase).
  • RNA transcripts can be directly transferred to the sequencing reactor (FIGURE 9) for mass spectrometric exonuclease sequencing using an immobilized or entrapped exonuclease.
  • the transcription process is initiated via initiator oligonucleotides with a 5' functionality allowing the subsequent immobilization of the RNA transcripts to a solid support [H. Koster, US Patent Application No. 08/001,323, supra]: in this case the mass spectrometric sequencing can be performed within the sequencing reactor using an exonuclease in solution.
  • the stepwise liberated ribonucleotides, or modified ribonucleotides i.e., ribonucleosides generated by passing through a reactor containing immobilized alkaline phosphatase), are fed to the mass spectrometer for sequence determination.
  • the throughput can be limited. However, in the present invention the throughput can be considerably increased by the introduction of mass-modified nucleotides into the DNA or RNA to be sequenced allowing for a parallel analysis of several nucleic acid sequences simultaneously by mass spectrometry. See H. Koster, US Patent Application No. 08/001.323. supra. Low molecular weight nucleic acid components, such as unmodified or mass modified nucleotides/nucleosides, can be analyzed simultaneously by multiplex mass spectrometry. Mass-modified nucleotides can be incorporated by way of mass modified nucleoside triphosphates precursors using various methods.
  • the unknown DNA sequence has been inserted in a restriction endonuclease site such as Not I.
  • standard procedures i.e., membrane filtration, molecular sieving, PAGE or agarose gel electrophoresis
  • the immobilized single- stranded DNA fragment with its B' boundary at the 3' end (i.e., Tr 3 ) is ready for exonuclease mediated mass spectrometric sequencing.
  • Tr 3 the immobilized single- stranded DNA fragment with its B' boundary at the 3' end
  • the same primer can be used even when the vector has no complementary Asc I site.
  • the primer will not hybridize with its 5' terminal sequence to the vector as is shown in FIGURE 3, it will nevertheless allow the covalent attachment of the single-stranded mass-modified DNA to the solid support using the same splint oligonucleotide as described above.
  • the primer can carry a non-restriction site sequence information at its 5' end, which may or may not be complementary to the opposite vector sequence, but is complementary to a specific splint oligodeoxynucleotide which allows the covalent attachment to the solid support.
  • a non-restriction site sequence information at its 5' end, which may or may not be complementary to the opposite vector sequence, but is complementary to a specific splint oligodeoxynucleotide which allows the covalent attachment to the solid support.
  • the latter two procedures do not require cleavage with a restriction endonuclease and separation of the strands.
  • the reaction mixture obtained after enzymatic synthesis of the mass-modified (-) strand can be directly joined to the solid support and the circular vector DNA and the stopper oligonucleotide can be removed under denaturing conditions.
  • the generation of a set of ordered deletions of the target DNA sequence information and the incorporation of mass modified nucleotides can be combined by terminating the DNA polymerase reaction at different time intervals (i.e., t ⁇ , t ⁇ , t ⁇ , t 3 , FIGURE 3) to generate a ladder of mass-modified (-) strands.
  • a circularization and cloning step as described above can be included.
  • both the (+) and (-) strand can be exonuclease sequenced simultaneously. Incorporation of mass-modified nucleotides in to one of the (+) or (-) strands can be carried out as described above. In the illustrative embodiment, both the (+) and (-) strands are ligated to solid supports and exonucleased simultaneously. The presence of the mass-modified nucleotides in the (-) strand can allow for differentiation of mass spectrometric signals arising from nucleotides released from both strands.
  • exonuclease sequencing can proceed essentially between the A and B boundaries in one pass, the sequence of the (-) strand can be inverted and aligned with the complimentary sequence.
  • An advantage to this approach is the identification of ambiguous sequencing data (i.e., base pair mismatches arising from error of sequencing one of the strands).
  • the full sequence can be obtained from partial exonuclease sequencing of both the (+) and (-) strands provided that sequencing proceeds to an overlaping point on each strand. By searching for the complementary overlapping region of each sequence fragment and aligning the two sequence fragments, the sequence of the remainder of one or both of the strands can be "reconstructed" based on the known sequence of the other.
  • RNA transcripts of both strands can be obtained utilizing, for example, transcription promoter regions flanking the insertion site, restoring the double-stranded promoter site by complementary oligonucleotides [Methods in Enzymology. Vol. 185. (1990): Uhlenbeck et al., Nucleic Acids Res.. (1987). supra] and transcribing with appropriate RNA polymerases in the presence of mass-modified ribonucleoside triphosphates.
  • the mass-modified RNA can be directly transferred to the sequencing reactor for mass spectrometric sequencing using an immobilized or entrapped exonuclease.
  • the transcription can be initiated with initiator oligonucleotides [Krupp et al., Gene. (1992). supra] carrying a 5' functionality for subsequent attachment of the mass- modified RNAs to a solid support.
  • the immobilized mass-modified RNAs can be contacted in the sequencing reactor (FIGURE 9) with an exonuclease in solution for mass spectrometric sequencing.
  • the mass-modification of the immobilized strand starting with the unknown DNA insert in a double-stranded vector can be introduced starting with a situation similar to Tr ⁇ ds in FIGURE 2.
  • a 5' phosphorylated exonuclease III resistant splint oligonucleotide i.e., 2',3' dideoxy
  • is ligated to the (-) strand allowing a unilateral digestion of the (+)strand with exonuclease III (FIGURE 4A).
  • the mass- modifications are then introduced by a filling-in reaction using template dependent DNA polymerases such as Sequenase, version 2.0 (US Biochemicals), Taq DNA polymerase or AMV reverse transcriptase and appropriate mass-modified dNTPs.
  • template dependent DNA polymerases such as Sequenase, version 2.0 (US Biochemicals), Taq DNA polymerase or AMV reverse transcriptase and appropriate mass-modified dNTPs.
  • This approach can also be carried out by generating a mass modified (+) strand starting with Tr ⁇ 'ss (FIGURE 4B).
  • the newly synthesized (+) strand can be isolated from the (-) strand solid support, such as by denaturation, and immobilized via the 5' sequence information of the primer and a splint oligonucleotide which is in part complementary to this and to an oligonucleotide sequence already attached to another solid support (FIGURE 4B).
  • the splint oligonucleotide is removed and the immobilized mass- modified single-stranded (+) DNA is transferred to the sequencing reactor (FIGURE 9) and contacted with an exonuclease, such as T4 DNA polymerase in solution, for mass spectrometric sequence determination via the released mass-modified nucleotides.
  • an exonuclease such as T4 DNA polymerase in solution
  • the mass-modifying functionality can be located at different positions within the nucleotide moiety (FIGURE 5 and 6). See also H. Koster, US Patent Application No. 08/001,323, for further examples and synthesis chemistries.
  • the mass-modifying functionality can be located at the heterocyclic base at position C-8 in purine nucleotides (Ml) or C-8 and/or C7 (M2) in c7-deazapurine nucleotides and at C-5 in uracil and cytosine and at the C-5 methyl group at thymine residues (Ml).
  • Modifications in these positions do not interfere with Watson-Crick specific base- pairing necessary for the enzymatic incorporation into the mass-modified nucleic acids (DNA/RNA) with high accuracy.
  • Modifications introduced at the phosphodiester bond (M4) such as with alpha-thio nucleoside triphosphates, have the advantage that these modifications do not interfere with accurate Watson-Crick base-pairing and additionally allow for the one- step post-synthetic site-specific modification of the complete nucleic acid molecule e.g. via alkylation reactions [K.L. Nakamaye, G. Gish, F. Eckstein and H.-P. Vossberg, Nucleic Acids Res.. 16. 9947-59 (1988)].
  • the tables in FIGURES 7 and 8 depict some examples of mass-modifying functionalites for nucleotides. This list is, however, not meant to be limiting, since numerous other combinations of mass modifying functions and positions within the nucleotide molecule are possible and are deemed part of the invention.
  • the mass modifying functionality can be, for example, a halogen, an azido, or of the type XR. Wherein X is a linking group and R is a mass modifying functionality.
  • the mass modifying functionality can thus be used to introduce defined mass increments into the nucleotide molecule.
  • the mass modification, M can be introduced for X in XR as well as using oligo-/polyethylene glycol derivatives for R.
  • the oligo/polyethylene glycols can also be monoalkylated by a lower alkyl such as methyl, ethyl, propyl, isopropyl, t-butyl and the like.
  • a selection of linking functionalities X are also illustrated in FIGURE 8.
  • Other chemistries can be used in the mass modified compounds, as for example, those described recently in Oligonucleotides and Analogues, A Practical Approach, F. Eckstein, editor, IRL Press, Oxford, 1991.
  • various mass modifying functionalities R can be selected and attached via appropriate linking chemistries X.
  • a simple mass modification can be achieved by substituting H for halogens like F, Cl, Br and/or I; or pseudohalogens such as SCN, NCS; or by using different alkyl, aryl or aralkyl moieties such as methyl, ethyl, propyl, isopropyl, t-butyl, hexyl, phenyl, substituted phenyl, benzyl; or functional groups such as CH2F, CHF2, CF3, Si(CH3)3, Si(CH3)2(C2H5), Si(CH3)(C2Hs)2, Si(C2H5)3 .
  • Yet another mass modification can be obtained by attaching homo- or heteropeptides through X to the nucleotide.
  • the mass modifying functionality can be introduced by a two or multiple step process.
  • the nucleotide is, in a first step, modified by a precursor functionality such as azido, -N3, or modified with a functional group in which the R in XR is H thus providing temporary functions e.g.
  • FIGURE 9 A schematic outlay of an exonuclease sequencer is shown in FIGURE 9.
  • the central part is the reactor S which has a cooling/heating mantle (2) and a frit or semipermeable membrane (4).
  • Several flasks (R1-R5) can be dedicated to supply reagents such as buffer solutions, enzyme, etc. through a cooling/heating coil T.
  • the nucleic acids are immobilized on beads or flat membrane disks placed in the reactor S, or alternatively, immobilized on the inner surface of the walls within the capillary E.
  • Exonuclease is added to the reactor in a controlled manner and the reaction mixture circulated through a loop maintained at a carefully controlled temperature.
  • the exonuclease can be immobilized in e.g. a capillary E beneath the reactor S or could be immobilized on beads or on a membrane or entrapped in a gel or kept in the reactor S by way of a semipermeable membrane.
  • aliquots can be fed either continuously or in pulses to the mass spectrometer either directly or through a reactor AP which contains, for instance, immobilized alkaline phosphatase or other mass-modifying reagents.
  • a reactor AP which contains, for instance, immobilized alkaline phosphatase or other mass-modifying reagents.
  • the liquid volume which is transferred to the mass spectrometer is too large, only a portion can be supplied while the remainder is separated from the flow stream by using a flow splitting device SP. Unused or excess solutions can be disposed of by the waste container W.
  • the reaction mixture of the exonuclease digestion is processed via a moving belt the liquid flow can be directed through this module prior to entering the mass spectrometer.
  • exonucleases can be used, such as snake venom phosphodiesterase,
  • E. coli exonuclease VII Mung Bean Nuclease
  • S 1 Nuclease S 1 Nuclease
  • exonuclease and exonuclease III as well as the exonuclease activity of some DNA polymerases such as E. coli DNA polymerase I, the Klenow fragment of DNA polymerase I, T4 or T7 DNA polymerases, Taq DNA polymerase, Deep Vent DNA polymerase, and Vent r DNA polymerase.
  • the activity of these exonucleases can be modulated, for instance, by shifting off the optimal pH and/or temperature range or by adding poisoning agents to the reaction mixture.
  • exonuclease activity can also be modulated by way of functional groups, such as at the C-2' position of the sugar moiety of the nucleotide building block or at the phosphodiester bond (i.e., M3/M4 in FIGURE 5 and 6).
  • the masses for the phosphate dianion are 329.209 for pdG, 313.210 for pdA, 304J96 for pdT and 289.185 for pdC
  • the enzymatic digestion would be initiated at all nucleic acid chains at the same time, and the nucleotides would be released in identical time intervals d and detected by their individual molecular weights one after the other by the mass spectrometer.
  • FIGURE 10 illustrates the signals versus time for the sequence 5'...A-T*-C-C- G-G-A 3'.
  • a significant increase in throughput can be further obtained by employing the principle of multiplex exonuclease sequencing.
  • the principle of this concept is illustrated in FIGURE 11.
  • the DNA fragments to be processed in parallel can be identified by fragment specific labels introduced by the mass modifying functionality M.
  • the target nucleic acid sequences can be mass- modified by using, for example, unmodified dNTP ⁇ s or NTP ⁇ -s (TrO), nucleoside triphosphates mass-modified with the same functional group, such as an additional methyl group at the heterocyclic base, using either dNTPl or NTP ⁇ (TrO) ?
  • i modified DNA fragments can be simultaneously exonuclease sequenced.
  • the i different DNA fragments can be immobilized on different membranes and a stack of such membranes placed into the reactor S (FIGURE 9) for simultaneous exonuclease mass spectrometric sequencing.
  • the mass spectrometrically detected nucleotide masses can be easily assigned to the parent nucleic acid fragments and thus several sequences can be detected simultaneously by the mass spectrometer. Even in the worst case when the same nucleotide, e.g. dT is at the same position in all sequences, processed in parallel the signal can be decoded due to the difference in mass between dT ⁇ , dT ⁇ , dT-2, dT 3 , ..., dT 1 .
  • the synchronization of exonuclease action can be improved by incorporating modified nucleotides (modified at C-2 1 or at the phosphodiester bond) into the otherwise unmodified or mass-modified nucleic acid fragments as set out above.
  • modified nucleotides modified at C-2 1 or at the phosphodiester bond
  • mass-modified nucleotide can also be introduced at the 3 ' end of the single stranded nucleic acid fragment (i.e., C-2' or phosphodiester bond modifications) to achieve a more uniform initiation of the exonuclease reaction.
  • a reduction of overlap of neighboring signals can be achieved by using a moving belt device as schematically shown in FIGURE 12.
  • a moving belt device as schematically shown in FIGURE 12.
  • the effect of the moving belt can be to help spread the appearance of sequentially released nucleotide/nucleoside signals as illustrated in FIGURE 13.
  • the width between consecutive, i.e., neighboring, signals can be increased with the speed of the moving belt.
  • FIGURE 12 illustrates a possible configuration of the moving belt module for exonuclease mediated mass spectrometric sequencing.
  • An endless metal ribbon (10) is driven with variable speed using a controllable stepping motor and appropriately positioned pulleys. Spring-loaded pulleys can be used to maintain a sufficiently high tension on the moving belt.
  • the sample is applied to the belt from the reactor module A (FIGURE 9) at a position which is in direct contact with a cooling/heating plate B.
  • the sample can be mixed with a matrix solution M prior to loading onto the belt. Crystal formation can be observed with a viewing device D (CCD camera and optics).
  • the container M can be used to mix the sample with a diluent or other reagent, enzyme, internal standard etc. at a mixing valve or vortex (12).
  • a mixing valve or vortex In the instance of relatively small molecules such as the released nucleotides, matrix is not essential for the laser desorption/ionization process to take place.
  • the belt 10 moves the sample under a laser source E (with appropriate optics) for desorption and ionization.
  • a heating element C such as a microwave source, can be placed near the surface of the returning belt, separated from the forward moving belt by an insulating shield I, to clean the surface of the metal ribbon belt 10 of any organic material prior to loading a new sample.
  • a washing station W can be integrated before the heating element C; in this case the function of the heating element C can be completely dry the metal ribbon prior to reloading of sample.
  • two differential vacuum pumping stages F and G are positioned before and after the laser targets the sample.
  • An electric field is applied after the second vacuum stage to accelerate the ions into the mass spectrometer.
  • mass analyzer a quadrupole can be used, though other mass analyzing configurations are known in the art and are within the scope of the invention.
  • this vacuum seal can be provided by the use of tunnel seals in a two-stage vacuum lock as previously described [Moini et al, (1991). supra].
  • the moving belt device can be used for a second dimension in multiplexing by applying s samples from s sequencing reactors A (FIGURE 9) simultaneously in different locations onto the moving belt. Desorption and ionization of these multiple samples is achieved by moving the laser beam with adjustable speed and frequency back and forth perpendicular to the direction of the moving belt.
  • Identification and assignment of the nucleotides/nucleosides detected to the various nucleic acid fragments can be achieved by second dimension multiplexing, i.e., by mass-labeling the nucleic acid fragments with for example -CH2-, -CH2CH2-, -CH2CH2CH2- and - CH2(CH2) r CH2-, and labeling the different reactors, for example, by individual halogen atoms, i.e., F for reactor 1 (thus having the different DNA fragments labeled with -CH2F, - CH 2 CH 2 F, -CH2CH 2 CH 2 F, -CH2(CH2)rCH F), Cl for reactor 2 (thus having the different DNA fragments labeled with -CH 2 C1, -CH CH C1, -CH 2 CH2CH 2 C1, -CH2(CH2) r CH Cl), Br for reactor 3 etc.
  • F for reactor 1
  • Cl for reactor 2
  • Cl thus having the different DNA fragments labeled with
  • Two-dimensional multiplexing can be applied in different ways. For example, it can be used to simultaneously sequence the fragments forming one set of overlapping deletions of the same long DNA insert. In another embodiment, several subsets of ordered deletions of different DNA inserts can be analyzed in parallel.
  • exonuclease mediated mass spectrometric DNA sequencing is that small molecules are analyzed and identified by mass spectrometry. In this mass range, the accuracy of mass spectrometers is routinely very high, i.e., OJ mass units are easily detected. This increases the potential for multiplexing as small differences in mass can be detected and resolved.
  • An additional advantage of mass spectrometric sequencing is that the identified masses can be registered automatically by a computer and by adding the time coordinate automatically aligned to sequences. Since the sequences so determined are memorized (i.e., saved to disk or resident in the computer memory) appropriate existing computer programs operating in a multitasking environment can be searching in the "background" (i.e., during continuous generation of new sequence data by the exonuclease mass spectrometric sequencer) for overlaps and generate contiguous sequence information which, via a link to a sequence data bank, can be used in homology searches, etc.
  • kits for sequencing nucleic acids by exonuclease mass spectrometry which include combinations of the above described sequencing reactants.
  • the kit comprises reagents for multiplex mass spectrometric sequencing of several different species of nucleic acid.
  • the kit can include an exonuclease for cleaving the nucleic acids unilaterally from a first end to sequentially release individual nucleotides, a set of nucleotides for synthesizing the different species of nucleic acids, at least a portion of the nucleotides being mass-modified such that sequentially released nucleotides of each of the different species of nucleic acids are distinguishable, a polymerase for synthesizing the nucleic acids from complementary templates and the set of nucleotides, and a solid support for immobilizing one of the nucleic acids or the exonuclease.
  • the kit can also include appropriate buffers, as well as instructions for performing multiplex mass spectrometry to concurrently sequence multiple species of nucleic acids.
  • the sequencing kit can include an exonuclease for cleaving a target nucleic acid unilaterally from a first end to sequentially release individual nucleotides, a set of nucleotides for synthesizing the different species of nucleic acids, at least a portion of the nucleotides being mass-modified to modulate the exonuclease activity, a polymerase for synthesizing the nucleic acid from a complementary template and the set of nucleotides, and a solid support for immobilizing one of the nucleic acids or the exonuclease.
  • Another aspect of this invention concerns a "reverse-Sanger” type sequencing method using exonuclease digestion of nucleic acids to produce a ladder of nested digestion fragments detectable by mass spectrometry.
  • the target nucleic acid can be immobilized to a solid support to provide unilateral degradation of the chain by exonuclease action.
  • Incorporating into the target nucleic acid a limited number of mass- modified nucleotides which inhibit the exonuclease activity i.e., protect an individual nucleic acid chain from further degradation
  • the nested exonuclease fragments can then be released from the solid support (i.e., via a cleavable linkage) and the molecular weight values for each species of the nested fragments determined by mass spectrometry, as described in U.S. Patent application No. 08/001,323. From the molecular weight values determined, the sequence of the nucleic acid can be generated. It is clear that many variations of this reaction are possible and that it is amenable to multiplexing.
  • the target nucleic acid need not be bound to a solid support, rather any protecting group can be used to ensure unilateral exonuclease degradation.
  • mass-modified nucleotides which have large enough molecular weight differences to be differentiated between by mass spectrometry (i.e., the termination of a chain with a particular mass-modified nucleotide is discernable from all other terminations)
  • the exonuclease sequencing can be carried out to create only one set of nested fragments.
  • individual types of exonuclease-inhibiting nucleotides can be incorporated in separate reactions to create sets of nested fragments.
  • four sets of nested fragments can be separately generated wherein one set terminates with mass- modified A's, one set terminates in mass-modified G's, etc. and the total sequence is determined by aligning the collection of nested exonuclease fragments.
  • SEQUELON membranes (Millipore Corp., Bedford, MA) with phenyl isothiocyanate groups is used as a starting material.
  • the membrane disks with a diameter of 8 mm, are wetted with a solution of N-methylmorpholine/water/2-propanol (NMM solution) (2/49/49;v/v/v), the excess liquid removed with filterpaper and placed on a piece of plastic film or aluminium foil located on a heating block set to 55°C
  • NMM solution N-methylmorpholine/water/2-propanol
  • the disks are stored with free thiol groups in a solution of 1M aqueous dithiothreitol/2-propanol (1:1; v/v) and, before use, DTT is removed by three washings with 1ml each of the NMM solution.
  • Single-stranded nucleic acid fragments with 5'-SH functionality can be prepared by various methods [e.g. B.C.F Chu et al., Nucl eic Acids Res., 14, 5591-5603 (1986), Sproat et al., Nucleic Acids Res., 15, 4837-48 (1987) and Oligonucleotides and Analogues. A Practical Approach (F. Eckstein editor), IRL Press Oxford, 1991].
  • the single-stranded nucleic acid fragments with free 5 '-thiol group are now coupled to the thiolated membrane supports under mild oxidizing conditions. In general it is sufficient to add the 5'-thiolated nucleic acid fragments dissolved in 10 ul 10 mM de ⁇ aerated triethylammonium acetate buffer (TEAA) pH 7.2 to the thiolated membrane supports; coupling is achieved by drying the samples onto the membrane disks with a cold fan. This process can be repeated by wetting the membrane with 10 ul of 10 mM TEAA buffer pH 7.2 and drying as before.
  • anchoring can be monitored by the release of pyridine-2-thione spectrophotometrically at 343 nm.
  • the single-stranded nucleic acid is functionalized with an amino group at the 5'-end by standard procedures.
  • the primary amino group is reacted with 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) and subsequently coupled to the thiolated supports and monitored by the release of pyridyl-2- thione as described above.
  • SPDP 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester
  • reaction mixture is vortexed and incubated for 30 min at 25oC; excess SPDP is then removed by three extractions (vortexing, centriftigation) with 50 ul each of ethanol and the resulting pellets dissolved in 10 ul 10 mM TEAA buffer pH 7.2 and coupled to the thiolated supports (see above).
  • the isolated nucleic acids can be released by three successive treatments with 10 ul each of 10 mM 2-mercaptoethanol in 10 mM TEAA buffer pH 7.2.
  • 5-Aminolevulinic acid is protected at the primary amino group with the Fmoc group using 9-fluorenylmethyl N-succinimidyl carbonate and then transformed into the N- hydroxysuccinimide ester (NHS ester) using N-hydroxysuccinimide and dicyclohexyl carbodiimide under standard conditions.
  • Nucleic acids which are functionalized with primary amino acid at the 5' end are EtOH precipitated and resuspended in 10 ul of 10 mM TEAA buffer pH 7.2.
  • Sequelon DITC membrane disks of 8 mm diameter (Millipore Corp. Bedford, MA) are wetted with 10 ul of NMM solution (N-methylmorpholine/propanaol-2/water; 2/49/49;v/v/v) and a linker arm introduced by reaction with 10 ul of a 10 mM solution of 1,6- diaminohexane in NMM.
  • NMM solution N-methylmorpholine/propanaol-2/water; 2/49/49;v/v/v
  • the excess of the diamine is removed by three washing steps with 100 ul of NMM solution.
  • the ethanol precipitated pellets are resuspended in 10 ul of a solution of N-methylmorpholine, propanol-2 and water (2/10/88; v/v/v) and transferred to the Lys-Lys-DITC membrane disks and coupled on a heating block set at 55°C After drying 10 ul of NMM solution is added and the drying process repeated.
  • the immobilized nucleic acids can be cleaved from the solid support by treatment with trypsin.
  • the DITC Sequelon membrane (disks of 8 mm diameter) are prepared as described in EXAMPLE 3 and 10 ul of a 10 mM solution of 3-aminopyridine adenine dinucleotide (APAD) (Sigma) in NMM solution added. The excess of APAD is removed by a 10 ul wash of NMM solution and the disks are treated with 10 ul of 10 mM sodium periodate in NMM solution (15 min, 25°C).
  • APAD 3-aminopyridine adenine dinucleotide
  • the ommobilized nucleic acids can be released from the solid support by treatment with either NADase or pyrophosphatase in 10 mM TEAA buffer at pH 7.2 at 37oC for 15 min.
  • NADase or pyrophosphatase in 10 mM TEAA buffer at pH 7.2 at 37oC for 15 min.
  • the reaction is terminated by the addition of water (5.0 ml), the reaction mixture evaporated in vacuo, co-evaporated twice with dry toluene (20 ml each) and the residue redissolved in 100 ml dichloromethane.
  • the solution is extracted successively, twice with 10 % aqueous citric acid (2 x 20 ml) and once with water (20 ml) and the organic phase dried over anhydrous sodium sulfate.
  • the organic phase is evaporated in vacuo, the residue redissolved in 50 ml dichloromethane and precipitated into 500 ml pentane and the precipitate dried in vacuo. Yield: 13.12 g (74.0 mmole; 74 %).
  • Nucleosidic starting material is as in previous examples, 5-(3-aminopropynyl- l)-2'-deoxyuridine.
  • the mass-modifying functionality is obtained similar to EXAMPLE 7. 12.02 g (100.0 mmole) freshly distilled diethylene glycol monomethyl ether dissolved in 50 ml absolute pyridine is reacted with 10.01 g (100.0 mmole) recrystallized succinic anhydride in the presence of 1.22 g (10.0 mmole) 4-N,N-dimethylaminopyridine (DMAP) overnight at room temperature.
  • DMAP 4-N,N-dimethylaminopyridine
  • This derivative is prepared in analogy to the glycine derivative of EXAMPLE 9. 632.5 mg (1.0 mmole) N6-Benzoyl-8-bromo-5'-O-(4,4 , -dimethoxytrityl)-2'-deoxy adenosine is suspended in 5 ml absolute ethanol and reacted with 324.3 mg (2.0 mmole) glycyl-glycine methyl ester in the presence of 241.4 mg (2J mmole, 366 ul) N,N- diisopropylethylamine. The mixture is refluxed and completeness of the reaction checked by TLC. Work-up and purification is similar as described in EXAMPLE 9. Yield after silica gel column chromatography and precipitation into pentane: 464 mg (0.65 mmole, 65 %).
  • reaction mixture is evaporated in vacuo, co-evaporated with toluene, redissolved in dichloromethane and purified by silica gel chromatography (Si60, Merck, column: 2.5x50 cm; eluent: chloroform/methanol mixtures containing 0.1 % triethylamine).
  • silica gel chromatography Si60, Merck, column: 2.5x50 cm; eluent: chloroform/methanol mixtures containing 0.1 % triethylamine.
  • the product containing fractions are combined, evaporated and precipitated into pentane. Yield: 524 mg (0.73 mmol; 73 %).
  • Solvents are removed by evaporation in vacuo, the residue is co-evaporated twice with toluene and condensed with 0.927 g (2.0 mmole) N-Fmoc-glycine pentafluorophenyl ester and purified following standard protocol. Yield: 445 mg (0.72 mmole; 72 %).
  • glycyl-, glycyl-glycyl- and ⁇ -alanyl-2'-deoxyuridine derivatives N-protected with the Fmoc group are now transformed to the 3'-O-acetyl derivatives by tritylation with 4,4-dimethoxytrityl chloride in pyridine and acetylation with acetic anhydride in pyridine in a one-pot reaction and subsequently detritylated by one-hour treatment with 80 % aqueous acetic acid according to standard procedures.
  • Yield of the 8-glycyl-2'-deoxyadenosine-5'-triphosphate is 57 % (0.57 mmole); the yield for the 8-glycyl- glycyl-2'-deoxyadenosine-5'-triphosphate is 51 % (0.51 mmole).
  • NAME DeConti, Giulio A.
  • MOLECULE TYPE other nucleic acid
  • HYPOTHETICAL YES
  • MOLECULE TYPE other nucleic acid
  • HYPOTHETICAL YES
  • MOLECULE TYPE other nucleic acid
  • HYPOTHETICAL YES
  • SEQUENCE DESCRIPTION SEQ ID NO:4 :
  • MOLECULE TYPE other nucleic acid
  • HYPOTHETICAL YES

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
EP94911643A 1993-03-19 1994-03-18 Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease Expired - Lifetime EP0689610B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3473893A 1993-03-19 1993-03-19
US34738 1993-03-19
PCT/US1994/002938 WO1994021822A1 (en) 1993-03-19 1994-03-18 Dna sequencing by mass spectrometry via exonuclease degradation

Publications (2)

Publication Number Publication Date
EP0689610A1 true EP0689610A1 (de) 1996-01-03
EP0689610B1 EP0689610B1 (de) 2002-07-03

Family

ID=21878288

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94911643A Expired - Lifetime EP0689610B1 (de) 1993-03-19 1994-03-18 Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease

Country Status (8)

Country Link
US (3) US5622824A (de)
EP (1) EP0689610B1 (de)
JP (1) JPH08507926A (de)
AT (1) ATE220114T1 (de)
AU (1) AU687801B2 (de)
CA (1) CA2158642A1 (de)
DE (1) DE69430909T2 (de)
WO (1) WO1994021822A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7159740B2 (en) 2001-10-26 2007-01-09 Sequenom, Inc. Method and apparatus for parallel dispensing of defined volumes of solid particles

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436635B1 (en) 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
US5795714A (en) * 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US6194144B1 (en) 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
US6074823A (en) * 1993-03-19 2000-06-13 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US20020037517A1 (en) * 1993-05-28 2002-03-28 Hutchens T. William Methods for sequencing biopolymers
EP0700521B1 (de) * 1993-05-28 2003-06-04 Baylor College Of Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
EP0765401B1 (de) * 1993-11-17 2001-02-21 Amersham Pharmacia Biotech UK Limited Verfahren zur massenspektroskopischen sequenzanalyse einer nukleinsäure mittels primerverlängerung
US6428955B1 (en) 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US7803529B1 (en) 1995-04-11 2010-09-28 Sequenom, Inc. Solid phase sequencing of biopolymers
US20060063193A1 (en) * 1995-04-11 2006-03-23 Dong-Jing Fu Solid phase sequencing of double-stranded nucleic acids
US5827659A (en) * 1995-05-19 1998-10-27 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers using mass spectrometry
US5869240A (en) * 1995-05-19 1999-02-09 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers with a statistical certainty using mass spectrometry
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
US6146854A (en) * 1995-08-31 2000-11-14 Sequenom, Inc. Filtration processes, kits and devices for isolating plasmids
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
EP0992511B1 (de) * 1996-01-23 2009-03-11 Operon Biotechnologies, Inc. Verfahren und Zusammensetzungen zur Bestimmung von Sequenzen von Nukleinsäure-Molekülen
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
AU2069597A (en) * 1996-03-04 1997-09-22 Genetrace Systems, Inc. Methods of screening nucleic acids using mass spectrometry
WO1997037041A2 (en) * 1996-03-18 1997-10-09 Sequenom, Inc. Dna sequencing by mass spectrometry
AU2462497A (en) 1996-04-17 1997-11-19 Hubert Koster A combinatorial protecting group strategy for multifunctional molecules
US5849546A (en) * 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5777324A (en) * 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5965363A (en) * 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
US5885775A (en) * 1996-10-04 1999-03-23 Perseptive Biosystems, Inc. Methods for determining sequences information in polynucleotides using mass spectrometry
US6140053A (en) * 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US6133436A (en) * 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US7285422B1 (en) 1997-01-23 2007-10-23 Sequenom, Inc. Systems and methods for preparing and analyzing low volume analyte array elements
DE69735112T2 (de) * 1996-11-06 2006-09-07 Sequenom, Inc., San Diego Verfahren zur Analyse und Vorrichtung
US6024925A (en) 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
EP1164203B1 (de) 1996-11-06 2007-10-10 Sequenom, Inc. DNA-Diagnostik mittels Massenspektrometrie
EP0963443B1 (de) 1996-12-10 2006-03-08 Sequenom, Inc. Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung
DE19714558A1 (de) * 1997-04-09 1998-10-15 Joachim W Prof Dr Engels Ein neues Verfahren zur Sequenzierung von Biopolymeren mit Massenspektrometrie
US6323482B1 (en) 1997-06-02 2001-11-27 Advanced Research And Technology Institute, Inc. Ion mobility and mass spectrometer
US6960761B2 (en) 1997-06-02 2005-11-01 Advanced Research & Technology Institute Instrument for separating ions in time as functions of preselected ion mobility and ion mass
US6498342B1 (en) 1997-06-02 2002-12-24 Advanced Research & Technology Institute Ion separation instrument
US5905258A (en) * 1997-06-02 1999-05-18 Advanced Research & Techology Institute Hybrid ion mobility and mass spectrometer
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP2001511358A (ja) 1997-07-28 2001-08-14 メディカル・バイオシステムズ・リミテッド 核酸配列の解析
US6245506B1 (en) 1997-07-30 2001-06-12 Bbi Bioseq, Inc. Integrated sequencing device
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US20110166040A1 (en) * 1997-09-05 2011-07-07 Ibis Biosciences, Inc. Compositions for use in identification of strains of e. coli o157:h7
CA2303790A1 (en) * 1997-09-15 1999-03-25 Brax Group Limited Characterising nucleic acid by mass spectrometry
US5952654A (en) * 1997-10-29 1999-09-14 Northeastern University Field-release mass spectrometry
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
US6407816B1 (en) * 1998-02-23 2002-06-18 Zygo Corporation Interferometer and method for measuring the refractive index and optical path length effects of air
WO1999044045A1 (en) * 1998-02-27 1999-09-02 Massachusetts Institute Of Technology Single molecule detection with surface-enhanced raman scattering and applications in dna or rna sequencing
US6703211B1 (en) 1998-03-13 2004-03-09 Promega Corporation Cellular detection by providing high energy phosphate donor other than ADP to produce ATP
US6335162B1 (en) 1998-03-13 2002-01-01 Promega Corporation Nucleic acid detection
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
US7090975B2 (en) 1998-03-13 2006-08-15 Promega Corporation Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection
US6270973B1 (en) 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US6391551B1 (en) 1998-03-13 2002-05-21 Promega Corporation Detection of nucleic acid hybrids
US6235480B1 (en) * 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
US6277578B1 (en) * 1998-03-13 2001-08-21 Promega Corporation Deploymerization method for nucleic acid detection of an amplified nucleic acid target
US6312902B1 (en) 1998-03-13 2001-11-06 Promega Corporation Nucleic acid detection
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
ATE256142T1 (de) 1998-05-15 2003-12-15 Isis Innovation Bibliotheken von unterschiedlich markierten oligomeren
US6104028A (en) 1998-05-29 2000-08-15 Genetrace Systems Inc. Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry
US6218118B1 (en) 1998-07-09 2001-04-17 Agilent Technologies, Inc. Method and mixture reagents for analyzing the nucleotide sequence of nucleic acids by mass spectrometry
US6270976B1 (en) 1998-09-15 2001-08-07 Brax Group Limited Characterizing nucleic acid by mass spectrometry
US6500650B1 (en) 1998-10-01 2002-12-31 Variagenics, Inc. Method for identifying polymorphisms
US6855500B2 (en) 1998-10-01 2005-02-15 Sequenom, Inc. Fluorescence-based genotyping
US6440705B1 (en) 1998-10-01 2002-08-27 Vincent P. Stanton, Jr. Method for analyzing polynucleotides
US6458945B1 (en) 1998-10-01 2002-10-01 Variagenics, Inc. Method for analyzing polynucleotides
US6994998B1 (en) 1998-10-01 2006-02-07 Sequenom, Inc. Base-modified nucleotides and their use for polymorphism detection
US6777188B2 (en) 1998-10-01 2004-08-17 Variagenics, Inc. Genotyping by mass spectrometric analysis of allelic fragments
US6566059B1 (en) 1998-10-01 2003-05-20 Variagenics, Inc. Method for analyzing polynucleotides
US6610492B1 (en) 1998-10-01 2003-08-26 Variagenics, Inc. Base-modified nucleotides and cleavage of polynucleotides incorporating them
WO2000053805A1 (en) * 1999-03-10 2000-09-14 Asm Scientific, Inc. A method for direct nucleic acid sequencing
US6225061B1 (en) 1999-03-10 2001-05-01 Sequenom, Inc. Systems and methods for performing reactions in an unsealed environment
US6605434B1 (en) 1999-03-16 2003-08-12 Human Genome Sciences, Inc. Direct bacterial lysate sequencing
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
US20020009394A1 (en) 1999-04-02 2002-01-24 Hubert Koster Automated process line
US6994969B1 (en) * 1999-04-30 2006-02-07 Methexis Genomics, N.V. Diagnostic sequencing by a combination of specific cleavage and mass spectrometry
DE60027309T2 (de) 1999-07-02 2006-08-31 Symyx Technologies, Inc., Santa Clara Polymerverzweigungen zur immobilisierung von molekülen auf oberflächen oder substraten, wobei die polymere wasserlösliche oder wasserdispergierbare segmente und sonden aufweisen
AU7105300A (en) 1999-09-03 2001-04-10 Lifebeam Technologies, Inc. Optical system for rapid polymer analysis
US6908736B1 (en) 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
GB9923644D0 (en) 1999-10-06 1999-12-08 Medical Biosystems Ltd DNA sequencing
US7668658B2 (en) * 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US7917301B1 (en) 2000-09-19 2011-03-29 Sequenom, Inc. Method and device for identifying a biological sample
CA2387035A1 (en) 1999-10-13 2001-04-19 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US20030207297A1 (en) * 1999-10-13 2003-11-06 Hubert Koster Methods for generating databases and databases for identifying polymorphic genetic markers
EP1313215B1 (de) * 1999-11-02 2012-05-02 ETA SA Manufacture Horlogère Suisse Temperaturkompensationsmechanismus für einen mikromechanischen ringresonator
FR2805826B1 (fr) * 2000-03-01 2002-09-20 Nucleica Nouvelles puces a adn
DE10015797B4 (de) * 2000-03-26 2006-02-02 Bruker Daltonik Gmbh Multiplex-Analyse von DNA-Gemischen mittels photolytisch ablesbarer DNA-Chips
JP2003532117A (ja) * 2000-04-13 2003-10-28 サーモ フィニガン リミテッド ライアビリティ カンパニー 並列質量分析によるプロテオミクス解析
US6552335B1 (en) 2000-06-13 2003-04-22 Cleveland State University SDIFA mass spectrometry
DE60137722D1 (de) * 2000-06-13 2009-04-02 Univ Boston Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20020142483A1 (en) 2000-10-30 2002-10-03 Sequenom, Inc. Method and apparatus for delivery of submicroliter volumes onto a substrate
WO2002056021A2 (en) * 2001-01-10 2002-07-18 Symyx Technologies Inc Polymer brushes for immobilizing molecules to a surface
US7718354B2 (en) * 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US20040121309A1 (en) * 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US20030027135A1 (en) * 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121310A1 (en) * 2002-12-18 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in forensic studies
US20040121314A1 (en) * 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in containers
EP1423400B2 (de) * 2001-03-19 2013-05-22 President and Fellows of Harvard College Entwicklung neuer molekularer funktionen
US20020155587A1 (en) 2001-04-20 2002-10-24 Sequenom, Inc. System and method for testing a biological sample
EP1401850A1 (de) * 2001-06-20 2004-03-31 Nuevolution A/S Nukleosidderivate zur herstellung einer verbindungsbibliothek
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
WO2003092581A2 (en) 2001-07-16 2003-11-13 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
AU2002364945A1 (en) * 2001-10-25 2003-07-09 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
AU2002364894A1 (en) * 2001-11-09 2003-06-30 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20030153007A1 (en) * 2001-12-28 2003-08-14 Jian Chen Automated systems and methods for analysis of protein post-translational modification
AU2003201159A1 (en) 2002-01-08 2003-07-24 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
AU2003224674A1 (en) * 2002-03-11 2003-09-29 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
US6723546B2 (en) * 2002-03-26 2004-04-20 New England Biolabs, Inc. Method for cloning and expression of BsaI restriction endonuclease and BsaI methylase in E. coli
US20030228571A1 (en) * 2002-04-01 2003-12-11 Ecker David J. Method for rapid detection and identification of viral bioagents
WO2003093296A2 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US6680477B2 (en) * 2002-05-31 2004-01-20 Battelle Memorial Institute High spatial resolution matrix assisted laser desorption/ionization (MALDI)
CA2494262A1 (en) 2002-07-31 2004-02-05 University Of Southern California Polymorphisms for predicting disease and treatment outcome
WO2004016767A2 (en) * 2002-08-19 2004-02-26 The President And Fellows Of Harvard College Evolving new molecular function
AU2003298733B2 (en) * 2002-11-27 2009-06-18 Agena Bioscience, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
US20040121312A1 (en) * 2002-12-18 2004-06-24 Ecker David J. Methods for rapid detection and identification of the absence of bioagents
US20040121315A1 (en) * 2002-12-18 2004-06-24 Ecker David J. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby
US20040122857A1 (en) * 2002-12-18 2004-06-24 Ecker David J. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby
WO2004064972A2 (en) 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20070141570A1 (en) * 2003-03-07 2007-06-21 Sequenom, Inc. Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US8017323B2 (en) * 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
EP1618216A2 (de) * 2003-04-25 2006-01-25 Sequenom, Inc. Auf fragmentierung beruhende verfahren und systeme zur de-novo-sequenzierung
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
EP2107129B1 (de) 2003-07-31 2012-08-22 Sequenom, Inc. Verfahren für Multiplex-Polymerasekettenreaktionen auf hohem Niveau und homogene Massenausdehnungsreaktionen zur Genotypisierung von Polymorphismen
US20050123952A1 (en) * 2003-09-04 2005-06-09 Griffey Richard H. Methods of rapid detection and identification of bioagents using microRNA
WO2005024068A2 (en) 2003-09-05 2005-03-17 Sequenom, Inc. Allele-specific sequence variation analysis
US20100035239A1 (en) * 2003-09-11 2010-02-11 Isis Pharmaceuticals, Inc. Compositions for use in identification of bacteria
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20060240412A1 (en) * 2003-09-11 2006-10-26 Hall Thomas A Compositions for use in identification of adenoviruses
US20100129811A1 (en) * 2003-09-11 2010-05-27 Ibis Biosciences, Inc. Compositions for use in identification of pseudomonas aeruginosa
US20080138808A1 (en) * 2003-09-11 2008-06-12 Hall Thomas A Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US7666592B2 (en) * 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
CA2561381C (en) 2004-03-26 2015-05-12 Sequenom, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US7608394B2 (en) 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
US20050266411A1 (en) * 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
JP2008512129A (ja) * 2004-09-10 2008-04-24 セクエノム，インコーポレイティド 核酸の広範囲配列分析法
JP5519088B2 (ja) * 2004-09-28 2014-06-11 ソニー株式会社 核酸分子塩基配列の決定方法及び決定装置
GB0424426D0 (en) 2004-11-04 2004-12-08 Micromass Ltd Mass spectrometer
US20060205040A1 (en) * 2005-03-03 2006-09-14 Rangarajan Sampath Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
US8785130B2 (en) 2005-07-07 2014-07-22 Bio-Id Diagnostic Inc. Use of markers including nucleotide sequence based codes to monitor methods of detection and identification of genetic material
JP2009502137A (ja) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド 核酸変種の迅速な同定および定量のための方法
US7738401B2 (en) * 2005-10-20 2010-06-15 At&T Intellectual Property I, L.P. System and method for overlaying a hierarchical network design on a full mesh network
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
EP2010679A2 (de) 2006-04-06 2009-01-07 Ibis Biosciences, Inc. Zusammensetzungen für die identifizierung von pilzen
US7858392B2 (en) * 2006-05-26 2010-12-28 Science And Engineering Services, Inc. Method and apparatus for processing of biological samples for mass spectrometry analysis
US9150906B2 (en) 2006-06-28 2015-10-06 Bio-Id Diagnostic Inc. Determination of variants produced upon replication or transcription of nucleic acid sequences
US7772390B1 (en) 2006-07-18 2010-08-10 The Regents Of The University Of California Lipid mediated nucleic acid synthesis
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8076104B2 (en) * 2007-01-25 2011-12-13 Rogan Peter K Rapid and comprehensive identification of prokaryotic organisms
EP2126132B1 (de) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Verfahren für schnelle forensische dna-analyse
US20100204266A1 (en) * 2007-03-23 2010-08-12 Ibis Biosciences, INC Compositions for use in identification of mixed populations of bioagents
US7811766B2 (en) * 2007-03-28 2010-10-12 Thinkvillage, Llc Genetic identification and validation of Echinacea species
US20090006002A1 (en) * 2007-04-13 2009-01-01 Sequenom, Inc. Comparative sequence analysis processes and systems
US8527207B2 (en) * 2007-05-15 2013-09-03 Peter K. Rogan Accurate identification of organisms based on individual information content
WO2009023358A2 (en) * 2007-05-25 2009-02-19 Ibis Biosciences, Inc. Compositions for use in identification of strains of hepatitis c virus
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2009038840A2 (en) * 2007-06-14 2009-03-26 Ibis Biosciences, Inc. Compositions for use in identification of adventitious contaminant viruses
EP2014761B1 (de) * 2007-06-22 2016-09-28 Sony Deutschland GmbH Vorrichtung zum Verarbeiten eines Analyten und Verfahren zum Verarbeiten und/oder Erkennen eines Analyten mittels dieser Vorrichtung
WO2009039122A2 (en) 2007-09-17 2009-03-26 Sequenom, Inc. Integrated robotic sample transfer device
US20110097704A1 (en) * 2008-01-29 2011-04-28 Ibis Biosciences, Inc. Compositions for use in identification of picornaviruses
US20110177515A1 (en) * 2008-05-30 2011-07-21 Ibis Biosciences, Inc. Compositions for use in identification of francisella
WO2009155103A2 (en) * 2008-05-30 2009-12-23 Ibis Biosciences, Inc. Compositions for use in identification of tick-borne pathogens
WO2009148995A2 (en) * 2008-06-02 2009-12-10 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
EP2316030B1 (de) 2008-07-25 2019-08-21 Wagner, Richard W. Proteinscreeningverfahren
US20100159506A1 (en) * 2008-07-25 2010-06-24 Cellscape Corporation Methods and systems for genetic analysis of fetal nucleated red blood cells
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
WO2010033625A1 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8921046B2 (en) 2008-09-19 2014-12-30 Pacific Biosciences Of California, Inc. Nucleic acid sequence analysis
US8481264B2 (en) * 2008-09-19 2013-07-09 Pacific Biosciences Of California, Inc. Immobilized nucleic acid complexes for sequence analysis
WO2010039696A1 (en) * 2008-10-02 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of herpesviruses
US20110189687A1 (en) * 2008-10-02 2011-08-04 Ibis Bioscience, Inc. Compositions for use in identification of members of the bacterial genus mycoplasma
US20110190170A1 (en) * 2008-10-03 2011-08-04 Ibis Biosciences, Inc. Compositions for use in identification of antibiotic-resistant bacteria
WO2010039870A1 (en) * 2008-10-03 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of neisseria, chlamydia, and/or chlamydophila bacteria
WO2010039848A2 (en) * 2008-10-03 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of streptococcus pneumoniae
US20110183343A1 (en) * 2008-10-03 2011-07-28 Rangarajan Sampath Compositions for use in identification of members of the bacterial class alphaproteobacter
WO2010039787A1 (en) * 2008-10-03 2010-04-08 Ibis Biosciences, Inc. Compositions for use in identification of clostridium difficile
WO2010080616A1 (en) 2008-12-19 2010-07-15 Abbott Laboratories Molecular assay for diagnosis of malaria
CA2741592A1 (en) * 2008-12-19 2010-06-24 Abbott Laboratories Diagnostic test for mutations in codons 12-13 of human k-ras
EP2396803A4 (de) 2009-02-12 2016-10-26 Ibis Biosciences Inc Ionisationssondenanordnungen
US9719083B2 (en) 2009-03-08 2017-08-01 Ibis Biosciences, Inc. Bioagent detection methods
WO2010114842A1 (en) 2009-03-30 2010-10-07 Ibis Biosciences, Inc. Bioagent detection systems, devices, and methods
WO2010123626A1 (en) 2009-04-24 2010-10-28 University Of Southern California Cd133 polymorphisms and expression predict clinical outcome in patients with cancer
US20110171619A1 (en) * 2009-05-28 2011-07-14 Daniel Leo Sweeney Representation of molecules as sets of masses of complementary subgroups and contiguous complementary subgroups
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
EP2454000A4 (de) 2009-07-17 2016-08-10 Ibis Biosciences Inc Systeme zur identifizierung von biowirkstoffen
WO2011014811A1 (en) 2009-07-31 2011-02-03 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
EP3098325A1 (de) 2009-08-06 2016-11-30 Ibis Biosciences, Inc. Basenzusammensetzungen ohne massenbestimmung zur nukleinsäureerkennung
US20110065111A1 (en) * 2009-08-31 2011-03-17 Ibis Biosciences, Inc. Compositions For Use In Genotyping Of Klebsiella Pneumoniae
US20110091882A1 (en) * 2009-10-02 2011-04-21 Ibis Biosciences, Inc. Determination of methylation status of polynucleotides
EP2488656B1 (de) 2009-10-15 2015-06-03 Ibis Biosciences, Inc. Mehrfache verschiebungsverstärkung
CA2780875A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US20120288861A1 (en) 2009-12-21 2012-11-15 Heinz-Josef Lenz Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer
WO2011085334A1 (en) 2010-01-11 2011-07-14 University Of Southern California Cd44 polymorphisms predict clinical outcome in patients with gastric cancer
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US8774488B2 (en) 2010-03-11 2014-07-08 Cellscape Corporation Method and device for identification of nucleated red blood cells from a maternal blood sample
US9758840B2 (en) 2010-03-14 2017-09-12 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
MX343607B (es) 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
EP2492688A1 (de) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
AU2012223136B2 (en) 2011-03-02 2017-05-25 Berg Llc Interrogatory cell-based assays and uses thereof
JP6040227B2 (ja) 2011-05-19 2016-12-07 アジーナ バイオサイエンス， インコーポレイテッド マルチプレックス核酸同定のための製品およびプロセス
BR112014004213A2 (pt) 2011-08-23 2017-06-20 Found Medicine Inc novas moléculas de fusão kif5b-ret e usos das mesmas
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2786156A2 (de) 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Verfahren und zusammensetzungen zur bestimmung des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
MX357392B (es) 2012-04-02 2018-07-06 Berg Llc Ensayos basados en interrogatorios celulares y uso de los mismos.
WO2014015098A1 (en) 2012-07-18 2014-01-23 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
AU2013296237B2 (en) 2012-08-03 2019-05-16 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
CA2889765C (en) 2012-10-26 2021-06-22 Minna D. BALBAS Androgen receptor variants and methods for making and using
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2805769A1 (de) 2013-05-24 2014-11-26 European Molecular Biology Laboratory Verfahren zur nanoskaligen Einzelzellenanalyse
US9670545B2 (en) 2013-06-11 2017-06-06 Coutagen Life Sciences, Inc. Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function
US20160138104A1 (en) 2013-06-18 2016-05-19 Universite De Montpellier Methods for determining the quality of an embryo
EP2818867A1 (de) 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) An mindestens ein Nucleinsäuremolekül konjugierte Antikörper und deren Verwendung in Multiplex-Immunnachweis-Assays
EP3016973A1 (de) 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Neuartige alternative splice-transkripte für ketten-alpha der mhc-klasse i (mica) und verwendungen davon
HK1224331A1 (zh) 2013-07-17 2017-08-18 Foundation Medicine, Inc. 治疗尿路上皮癌的方法
US10668055B2 (en) 2013-12-20 2020-06-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US11007183B2 (en) 2013-12-20 2021-05-18 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
EP4389225A3 (de) 2013-12-20 2024-10-09 Biomed Valley Discoveries, Inc. Krebsbehandlungen unter verwendung von kombinationen aus typ-2-mek- und erk-hemmern
WO2015095840A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
AU2016250841A1 (en) 2015-04-24 2017-11-02 Agena Bioscience, Inc. Multiplexed method for the identification and quantitation of minor alleles and polymorphisms
US10640817B2 (en) 2015-04-24 2020-05-05 Agena Bioscience, Inc. Multiplex methods for detection and quantification of minor variants
DK3347487T3 (da) 2015-09-11 2021-08-09 Inst Nat Sante Rech Med Ikke-invasive fremgangsmåder til vurdering af genetisk integritet af pluripotente stamceller
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3475706B1 (de) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018132639A1 (en) 2017-01-13 2018-07-19 Foster Charles Stephen Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US12359243B2 (en) 2020-05-04 2025-07-15 Northeastern University DNA adductomics by mass tag prelabeling
EP4479080A1 (de) 2022-02-16 2024-12-25 Dana-Farber Cancer Institute, Inc. Verfahren zur verringerung von pathologischem alpha-synuklein unter verwendung von mitteln zur modulation von fndc5 oder biologisch aktiven fragmenten davon
EP4507790A1 (de) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur universellen tumorzellabtötung
WO2025240660A1 (en) 2024-05-15 2025-11-20 Foresite Labs, Llc Drug development and drug activity determination for coronary artery disease (cad)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962037A (en) * 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
SE8801070D0 (sv) * 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
NZ229510A (en) * 1988-06-15 1991-08-27 Tanning Technologies Pty Ltd Treatment of hides: applying treating fluid to stretched hide
US5003059A (en) * 1988-06-20 1991-03-26 Genomyx, Inc. Determining DNA sequences by mass spectrometry
US5174962A (en) * 1988-06-20 1992-12-29 Genomyx, Inc. Apparatus for determining DNA sequences by mass spectrometry
US5002868A (en) * 1988-07-20 1991-03-26 Atom Sciences, Inc. DNA sequencing process using stable isotopes
US4997928A (en) * 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
FR2636738B1 (fr) * 1988-09-20 1992-12-11 Commissariat Energie Atomique Procede et installation de sequencage de l'adn
FR2636739B1 (fr) * 1988-09-20 1993-02-12 Commissariat Energie Atomique Procede et installation d'identification des bases d'un adn
DE3930312A1 (de) * 1988-10-24 1990-04-26 Max Planck Gesellschaft Verfahren zur direkten sequenzierung von nukleinsaeureketten
DK175170B1 (da) * 1988-11-29 2004-06-21 Sangtec Molecular Diagnostics Fremgangsmåde og reagenskombination til bestemmmelse af nukleotidsekvenser
KR920700360A (ko) * 1989-03-22 1992-02-19 하리크 프리드리히 미끄럼 베어링
JP2901004B2 (ja) * 1989-04-12 1999-06-02 株式会社日立製作所 Ｄｎａの塩基配列決定法
CA2032490A1 (en) * 1989-05-19 1990-11-20 Chin Kai Meng Multiply charged ions and a method for determining the molecular weight of large molecules
US5112736A (en) * 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US5366860A (en) * 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
WO1991006678A1 (en) * 1989-10-26 1991-05-16 Sri International Dna sequencing
WO1991011533A1 (en) * 1990-01-26 1991-08-08 E.I. Du Pont De Nemours And Company Method for isolating primer extension products from template-directed dna polymerase reactions
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
GB9016163D0 (en) * 1990-07-24 1990-09-05 Cemu Bioteknik Chemical method
WO1992002635A1 (en) * 1990-08-07 1992-02-20 E.I. Du Pont De Nemours And Company Method for determining dna sequences
GB9017788D0 (en) * 1990-08-14 1990-09-26 Medical Res Council Method for preparing,isolating and sequencing polynucleotides
EP0612994A3 (de) * 1993-02-26 1996-03-06 Ciba Geigy Ag Matrix für die matrix-unterstützte Laserdesorptions-Massenspektroskopie.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9421822A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7159740B2 (en) 2001-10-26 2007-01-09 Sequenom, Inc. Method and apparatus for parallel dispensing of defined volumes of solid particles

Also Published As

Publication number Publication date
US5872003A (en) 1999-02-16
JPH08507926A (ja) 1996-08-27
US5851765A (en) 1998-12-22
ATE220114T1 (de) 2002-07-15
CA2158642A1 (en) 1994-09-29
WO1994021822A1 (en) 1994-09-29
EP0689610B1 (de) 2002-07-03
AU687801B2 (en) 1998-03-05
AU6411694A (en) 1994-10-11
DE69430909T2 (de) 2003-02-27
US5622824A (en) 1997-04-22
DE69430909D1 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
EP0689610B1 (de) Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US6140053A (en) DNA sequencing by mass spectrometry via exonuclease degradation
US6074823A (en) DNA sequencing by mass spectrometry via exonuclease degradation
EP0679196B1 (de) Dns - sequenzierung durch massenspektronomie
US5541313A (en) Single-stranded labelled oligonucleotides of preselected sequence
US7001725B2 (en) Kits employing generalized target-binding e-tag probes
US6194144B1 (en) DNA sequencing by mass spectrometry
EP0135587B1 (de) Einzelstrang-oligonukleotide bestimmter sequenz, markergruppen enthaltend, verfahren zu deren chemischer synthese und nukleotide zur verwendung darin
US6770439B2 (en) Sets of generalized target-binding e-tag probes
JP3437184B2 (ja) 切断可能なプライマーを用いるオリゴヌクレオチドサイズ計測
WO1997037041A2 (en) Dna sequencing by mass spectrometry
WO1997037041A9 (en) Dna sequencing by mass spectrometry
CA2243637A1 (en) Nucleoside analogues
AU738203B2 (en) DNA sequencing by mass spectrometry
AU694940C (en) DNA sequencing by mass spectrometry

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19960705

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOESTER, HUBERT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUENOM, INC.

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20020703

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020703

REF Corresponds to:

Ref document number: 220114

Country of ref document: AT

Date of ref document: 20020715

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69430909

Country of ref document: DE

Date of ref document: 20020808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021003

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021003

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021003

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030318

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030331

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030404

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1013850

Country of ref document: HK

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20130314

Year of fee payment: 20

Ref country code: GB

Payment date: 20130313

Year of fee payment: 20

Ref country code: FR

Payment date: 20130325

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69430909

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20140317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20140317

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20140319